financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Buy Opinion On Shares Of Guardant Health, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Buy Opinion On Shares Of Guardant Health, Inc.
May 24, 2024 9:15 AM

11:55 AM EDT, 05/24/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $3 to $28, reflecting a 3.5x multiple of our 2025 revenue estimate, a discount to GH's historical average due to a long horizon until break-even cash flows are reached. GH announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration's (FDA) Medical Devices Advisory Committee has strongly recommended FDA approval of the company's Shield blood test for colorectal cancer screening in adults aged 45 and older who are at average risk for the disease. This indicated their conclusion that the test's benefits as a primary non-invasive screening option outweigh any potential risks (seven to two favorably on the advisory committee). The FDA is expected to decide whether to approve Shield later this year; we believe this recommendation makes FDA approval more likely.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Microsoft Corp.
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Microsoft Corp.
May 25, 2025
10:40 AM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We hold our 12-month target at $490, on a P/E of 32.8x our CY 26 view, which compares to its three-/five-year historical forward averages of 30.1x/31.1x given growth prospects tied...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Kkr & Co. Inc.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Kkr & Co. Inc.
May 25, 2025
11:40 AM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our target price by $32 to $143 using a narrower equity risk premium and a more conservative forward P/E of 27.0x in line with the five-year historic average....
Research Alert: CFRA Lifts Opinion On Shares Of Sprouts Farmers Market, Inc. To Buy From Hold
Research Alert: CFRA Lifts Opinion On Shares Of Sprouts Farmers Market, Inc. To Buy From Hold
May 25, 2025
10:55 AM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target to $205 from $149, or 35x our 2026 EPS estimate of $5.85 (up from $5.51; 2025 EPS raised to $5.16 from $4.82) vs. the 20x...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Meta Platforms Inc.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Meta Platforms Inc.
May 25, 2025
08:10 AM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target to $650 from, on a P/E of 23.6x our 2026 EPS view, within its long-term historical range. We raise our 2025 EPS estimate to $25.52...
Copyright 2023-2025 - www.financetom.com All Rights Reserved